BioDelivery Sciences International

BioDelivery Sciences ("BDSI"®) is a specialty pharmaceutical company with a focus in the areas of pain management and addiction medicine. We are utilizing our novel and proprietary BioErodible MucoAdhesive (BEMA®) and other drug delivery technologies to develop and commercialize, either on our own or in partnership with third parties, new applications of proven therapies aimed at addressing important unmet medical needs. Our development strategy focuses on utilization of the Food and Drug Administration's (FDA's) 505(b)(2) approval process. This regulatory pathway allows us to potentially obtain more timely and efficient approval of new formulations of previously approved therapeutics. Our particular area of focus is the development and commercialization of products in the areas of pain management and addiction medicine. These are areas where we believe our drug delivery technologies and products can best be applied to address critical unmet medical needs. Our marketed products and those in development address serious and debilitating conditions such as breakthrough cancer pain, chronic pain, painful diabetic neuropathy and opioid dependence. We look to improve upon existing drugs by enhancing their efficacy and/or ease of administration, or create new therapies, all with the ultimate goal of enhancing patient care.
Company Growth (employees)
Type
Public
HQ
Raleigh, US
Founded
1997
Size (employees)
40 (est)
Website
bdsi.com
BioDelivery Sciences International was founded in 1997 and is headquartered in Raleigh, US

Key People at BioDelivery Sciences International

Frank E. O'Donnell, Jr.

Frank E. O'Donnell, Jr.

Executive Chairman
Mark A. Sirgo

Mark A. Sirgo

Senior Vice President of Commercialization and Corporate Development
Albert J. Medwar

Albert J. Medwar

Vice President, Marketing and Corporate Development
William B. Stone

William B. Stone

Lead Director

BioDelivery Sciences International Office Locations

BioDelivery Sciences International has an office in Raleigh
Raleigh, US (HQ)
225 4131 Parklake Ave

BioDelivery Sciences International Data and Metrics

BioDelivery Sciences International Financial Metrics

BioDelivery Sciences International's revenue was reported to be $29.5 m in Q1, 2017
USD

Revenue (Q1, 2017)

29.5 m

Gross profit (Q1, 2017)

23.8 m

Gross profit margin (Q1, 2017), %

81%

EBIT (Q1, 2017)

7.9 m

Market capitalization (22-Aug-2017)

171.7 m

Cash (31-Mar-2017)

35.2 m
BioDelivery Sciences International's current market capitalization is $171.7 m.
USDFY, 2013FY, 2014FY, 2015FY, 2016

Revenue

11.4 m38.9 m48.2 m15.5 m

Revenue growth, %

243%24%(68%)

Cost of goods sold

4.9 m8.1 m11.3 m

Gross profit

34 m40.1 m4.3 m

Gross profit Margin, %

87%83%28%

EBIT

(56.4 m)(38.7 m)(35.2 m)(63.9 m)

EBIT margin, %

(497%)(99%)(73%)(411%)

Pre tax profit

(57.4 m)(54.2 m)

Net Income

(57.4 m)(54.2 m)(37.7 m)(67.1 m)
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Revenue

13.9 m1.8 m13.1 m1.7 m1.2 m3 m5 m3.6 m29.5 m

Cost of goods sold

462.8 k1.1 m2.6 m1.7 m2.6 m4.1 m2.3 m5.6 m

Gross profit

1.4 m11.9 m(888 k)(464 k)490 k910 k1.3 m23.8 m

Gross profit Margin, %

75%91%(51%)(38%)16%18%35%81%

R&D expense

8 m6.8 m6.5 m4.5 m4.5 m5.4 m4 m4.4 m2.7 m

General and administrative expense

7.2 m13.6 m13.2 m13.3 m14.7 m13.1 m12.5 m12.1 m13.3 m

Operating expense total

15.2 m20.4 m19.7 m17.8 m19.2 m18.4 m16.5 m16.5 m15.9 m

EBIT

(2 m)(19.1 m)(7.8 m)(18.7 m)(19.7 m)(17.9 m)(15.6 m)(15.2 m)7.9 m

EBIT margin, %

(15%)(1046%)(60%)(1078%)(1591%)(590%)(312%)(426%)27%

Interest expense

514.7 k420 k527 k785 k778 k914 k786 k2.9 m

Income tax expense

16 m

Net Income

(19.2 m)(20.4 m)(18.7 m)(16.5 m)(16 m)
USDFY, 2013FY, 2014FY, 2015FY, 2016

Cash

23.2 m70.5 m83.6 m32 m

Accounts Receivable

2.8 m3.1 m2.5 m3.6 m

Inventories

630.7 k2.9 m3.9 m3.4 m

Current Assets

26.6 m78.3 m92.5 m43.1 m

PP&E

3.9 m4.3 m4.2 m

Goodwill

2.7 m2.7 m2.7 m2.7 m

Total Assets

38 m89.3 m102.8 m52.3 m

Accounts Payable

18.2 m

Current Liabilities

25 m29.2 m28.1 m19.9 m

Total Liabilities

70 m

Additional Paid-in Capital

150.5 m259.9 m274.9 m292.7 m

Retained Earnings

(151.3 m)(205.5 m)(243.2 m)(310.3 m)

Total Equity

54.4 m31.7 m

Financial Leverage

1.6 x3.2 x
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Cash

78.4 m85.8 m63.5 m67.7 m54.4 m69.4 m57.5 m44.7 m35.2 m

Accounts Receivable

12.6 m205.2 k3 m1.5 m1.4 m2.1 m2.4 m3.1 m7.1 m

Inventories

795.4 k2 m2.6 m1.5 m1.9 m4.8 m4.4 m4 m8.1 m

Current Assets

92.4 m89.5 m71.7 m73.5 m61.3 m80.2 m67.9 m56.3 m54.4 m

PP&E

3.9 m4.3 m4.3 m4.4 m4.3 m4.3 m4.5 m

Goodwill

2.7 m2.7 m2.7 m2.7 m2.7 m2.7 m2.7 m2.7 m2.7 m

Total Assets

103.8 m101.1 m82.5 m84.9 m72.4 m90.3 m77.7 m65.8 m107.6 m

Accounts Payable

9.5 m13.1 m14.5 m12.3 m15 m19.1 m19.1 m18.8 m30.5 m

Current Liabilities

28.9 m34.5 m29.6 m20.5 m26.2 m30.4 m28.7 m32.3 m30.5 m

Additional Paid-in Capital

224.4 m242 m263.6 m267.8 m273.1 m281.7 m285.1 m289.3 m300.2 m

Retained Earnings

(162.6 m)(187.9 m)(213.7 m)(232.9 m)(253.4 m)(261.9 m)(278.4 m)(294.4 m)(262 m)

Total Equity

61.8 m54.1 m49.8 m34.9 m19.7 m19.8 m6.7 m38.2 m

Financial Leverage

1.7 x1.9 x1.7 x2.4 x3.7 x4.6 x11.7 x2.8 x
USDFY, 2013FY, 2014FY, 2015FY, 2016

Net Income

(57.4 m)(54.2 m)(37.7 m)(67.1 m)

Depreciation and Amortization

1.3 m1.1 m1.3 m1.4 m

Accounts Receivable

(2.3 m)(347 k)653 k(1.1 m)

Inventories

(1.8 m)(730 k)(810 k)

Accounts Payable

(656.8 k)4.3 m5.1 m(1.3 m)

Cash From Operating Activities

(60.1 m)(28.8 m)(3.7 m)(54 m)

Purchases of PP&E

(76.9 k)(1.6 m)(701 k)(405 k)

Cash From Investing Activities

(76.9 k)(1.6 m)(701 k)(405 k)

Cash From Financing Activities

20.2 m77.7 m17.5 m2.8 m

Interest Paid

742.1 k1.4 m1.9 m2.9 m

Income Taxes Paid

80.5 k80 k80 k
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Net Income

(19.2 m)(20.4 m)(18.7 m)(16.5 m)(16 m)

Accounts Receivable

12.6 m205.2 k3 m1.5 m1.4 m2.1 m2.4 m3.1 m7.1 m

Inventories

795.4 k2 m2.6 m1.5 m1.9 m4.8 m4.4 m4 m8.1 m
USDY, 2017

Revenue/Employee

737 k

Financial Leverage

2.8 x

BioDelivery Sciences International Market Value History

Traffic Overview of BioDelivery Sciences International

BioDelivery Sciences International Online and Social Media Presence

BioDelivery Sciences International Company Life and Culture

You may also be interested in